Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: 2 - The Real Truth

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

Benzinga

Recursion Pharmaceuticals's Return On Capital Employed Insights

Recursion Pharmaceuticals (NASDAQ:RXRX) brought in sales totaling $2.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 36.91%, resulting in a loss of $64.93 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

1 2

Organisations

Recursion Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.